🔴 Telix Pharmaceuticals is trading 5% down today after post-approval profit-taking

Telix Pharmaceuticals is trading at A$16.87 (-4.96%) after investors took profits following Pixclara’s FDA approval.

• The decline follows the prior session’s 8.63% rally.
• Broader biotech weakness pressured sentiment, with the XBI ETF down 2.11% during the session.
• The move appears amplified by sector weakness rather than a negative change to Pixclara’s approval.